David Shaw’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

David Shaw’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-666,171	Closed	-$6.68M	–	5310
2022 Q3	$6.68M	Hold	666,171	–	–	0.01%	1759
2022 Q2	$6.59M	Buy	666,171 +162,000	+32%	+$1.6M	0.01%	1798
2022 Q1	$4.97M	Buy	504,171 +25,502	+5%	+$250K	﹤0.01%	2316
2021 Q4	$4.67M	Buy	478,669 +302,988	+172%	+$2.97M	﹤0.01%	2447
2021 Q3	$1.72M	Buy	175,681 +54,646	+45%	+$533K	﹤0.01%	3176
2021 Q2	$1.19M	Buy	+121,035	New	+$1.19M	﹤0.01%	3399

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

David Shaw's EUCR Position: Q4 2022 in Review

David Shaw sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 666,171 shares — an estimated $6.68M sold.

David Shaw first reported a position in EUCR in Q2 2021 and held it in 6 quarters. The position peaked at $6.68M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

David Shaw reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
David Shaw sold 666,171 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $6.68M.
David Shaw first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q2 2021 and held it in 6 quarters.
David Shaw's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $6.68M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.